This chapter explores gender-specific medicine within the context of pharmaceutical development and global health care. It analyzes the challenges that the pharmaceutical industry (and by implication academia, regulators, and federal funding agencies) faces in integrating our growing knowledge on sex-specific biological differences in their drug development programs. Specifically, the chapter addresses the question of why the pharmaceutical industry has been so slow at incorporating gender differences in constructing their commercial portfolios. Finally, I emphasize the importance that gender-specific pharmaceuticals would have in global health care.
Principles of Gender-Specific Medicine (Third Edition), Gender in the Genomic Era, 2017, Pages 733-741,